The Drug-Induced Respiratory Disease Website and App

Corticosteroids, systemic (oral, parenteral)

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LIX.b

Opportunistic pulmonary/systemic infections

Publications

Bloechliger M, Reinau D, Spoendlin J, Chang SC, Kuhlbusch K, Heaney LG, Jick SS, Meier CR

Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis.

Respiratory research 2018 04 27;19;75 — 2018 04 27 — 75

Wilson JC, Sarsour K, Collinson N, Tuckwell K, Musselman D, Klearman M, Napalkov P, Jick SS, Stone JH, Meier CR

Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis.

Seminars in arthritis and rheumatism 2017 06;46;819-827 — 2017 06 — 819-827

Aljebab F, Choonara I, Conroy S

LONG-COURSE ORAL CORTICOSTEROID TOXICITY IN CHILDREN.

Archives of disease in childhood 2016 Sep;101;e2 — 2016 Sep — e2

Yamagata M, Hirose K, Ikeda K, Nakajima H

Clinical characteristics of Nocardia infection in patients with rheumatic diseases.

Clinical & developmental immunology 2013;2013;818654 — 2013 — 818654

Choi YR, Kim JT, Kim JE, Jung HW, Choe KH, Lee KM, An JY

Invasive aspergillosis involving the lungs and brain after short period of steroid injection: a case report.

Tuberculosis and respiratory diseases 2012 May;72;448-51 — 2012 May — 448-51

Yoo HG, Yu HM, Jun JB, Jeon HS, Yoo WH

Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide.

Modern rheumatology 2013 Jul;23;709-15 — 2013 Jul — 709-15

Hamilos G, Samonis G, Kontoyiannis DP

Pulmonary mucormycosis.

Seminars in respiratory and critical care medicine 2011 Dec;32;693-702 — 2011 Dec — 693-702

Bollée G, Sarfati C, Thiéry G, Bergeron A, de Miranda S, Menotti J, de Castro N, Tazi A, Schlemmer B, Azoulay E

Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients.

Chest 2007 Oct;132;1305-10 — 2007 Oct — 1305-10

Bernatsky S, Hudson M, Suissa S

Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis.

Rheumatology (Oxford, England) 2007 Jul;46;1157-60 — 2007 Jul — 1157-60

Datta D, Ali SA, Henken EM, Kellet H, Brown S, Metersky ML

Pneumocystis carinii pneumonia: the time course of clinical and radiographic improvement.

Chest 2003 Nov;124;1820-3 — 2003 Nov — 1820-3

Agustí C, Rañó A, Filella X, González J, Moreno A, Xaubet A, Torres A

Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response.

Chest 2003 Feb;123;488-98 — 2003 Feb — 488-98

Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE

Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.

The American journal of medicine 1994 Feb;96;115-23 — 1994 Feb — 115-23

Wiest PM, Flanigan T, Salata RA, Shlaes DM, Katzman M, Lederman MM

Serious infectious complications of corticosteroid therapy for COPD.

Chest 1989 Jun;95;1180-4 — 1989 Jun — 1180-4